Antiangiogenic drugs for chemotherapy of bladder tumours.

Article Details

Citation

Rocchetti R, Talevi S, Margiotta C, Calza R, Corallini A, Possati L

Antiangiogenic drugs for chemotherapy of bladder tumours.

Chemotherapy. 2005 Oct;51(6):291-9. Epub 2005 Oct 13.

PubMed ID
16224178 [ View in PubMed
]
Abstract

BACKGROUND: Bladder cancers have different angiogenic pathways distinguishing not only papillary from solid tumours, but even papillary superficial from papillary invasive ones, thus representing selective targets for antiangiogenic drugs. METHODS: The bacterial wall component tecogalan, inhibiting basic fibroblast growth factor (bFGF), the fumagillin derivative TNP-470, inhibiting vascular endothelial growth factor (VEGF), the distamycin A derivative PNU153429, and the tetracycline minocycline were administered to nude mice injected with the human bladder cancer cell lines 639V, causing bFGF-expressing papillary superficial tumours, or T24, causing VEGF-expressing papillary invasive tumours. RESULTS: Tecogalan had no effect even on 639V tumour growth, where bFGF was unaffected. TNP-470 only had an effect on T24 tumours, delaying tumour appearance and growth and lowering VEGF; these effects were augmented by adding minocycline. PNU153429 had no effect on 639V tumours, and a slight effect on T24 tumours. CONCLUSION: TNP-470 may represent a selective drug for the treatment of VEGF-expressing invasive papillary bladder tumours.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
MinocyclineVascular endothelial growth factor AProteinHumans
Unknown
Inhibitor
Details